"Ladies and gentlemen of the jury, has the treatment worked?" In kidney cancer, that verdict often comes from scans taken weeks or months later, which is a bit like judging a restaurant by checking the trash out back instead of tasting the food. This new paper asks a smarter question: can we catch the immune system in the act while it is actually attacking the tumor? Yang et al., 2026
That is the puzzle piece here. In renal cell carcinoma, or RCC, immunotherapy can help some patients a lot, but not everyone, and doctors still lack a reliable, real-time way to tell who is responding early on. Reviews in the field keep circling the same headache: biomarkers for immunotherapy in RCC are badly needed, but the ones we have are inconsistent, late, or too blunt to capture the actual street fight happening inside the tumor microenvironment Rosellini et al., 2023.
The Tiny Bodyguards Need a Better Microphone
The stars of this story are cytotoxic T lymphocytes, your immune system's licensed bouncers. When they recognize a cancer cell, they release granzyme B, a protein that helps kill the target. So if you could measure granzyme B in or around a tumor, you would get a readout of immune activity that is much closer to the action than waiting for the tumor to visibly shrink.
That idea is not brand new. Other groups have already built granzyme B-sensitive probes and shown that they can light up when immune cells are doing their job Scott et al., 2022. The catch is that many probes are "always on" or do not clear well through the kidneys, which is especially awkward when your cancer lives in the kidney. Designing a kidney-cancer sensor that does not behave like a drunk tourist in Times Square is harder than it sounds.
Bioorthogonal Chemistry, Aka Sneaky Chemistry With Manners
This paper uses bioorthogonal chemistry, which is chemist-speak for reactions that can happen inside living systems without barging into everybody else's business. The authors built near-infrared fluorogenic reporters that stay quiet until they meet the right biological conditions.
Their probe is tuned to respond to granzyme B, but it also uses a second lock tied to the tumor environment. In the RCC mouse models, the reporter accumulated in the kidney tumor, got activated by glutathione plus granzyme B, then turned fluorescent. That matters because it cuts background noise. Instead of a flashlight that is already on in your pocket, you get something closer to a motion-activated porch light.
The neat extra twist is renal clearance. The probe was designed to clear through the kidney, which makes it useful not just for imaging but also for urine-based detection. That is the part where the larger puzzle suddenly clicks. If a treatment response leaves a signal you can detect in urine, you are no longer limited to staring at anatomy and hoping biology eventually sends a postcard.
What They Actually Found
In mice receiving immunotherapy, the reporters distinguished stronger from weaker treatment responses by tracking granzyme B-linked immune activation in renal tumors. The authors then tested urine specimens from 21 patients with RCC and reported that the approach could sensitively stratify immune activation before and after treatment Yang et al., 2026.
That is the intriguing part. Not "we cured kidney cancer with magic glow juice." More like: "we may have built a better surveillance camera for the immune response." And honestly, that is valuable. One of the nastiest problems in cancer care is not just choosing a therapy, but knowing early whether the therapy deserves another month of the patient's time, side effects, and optimism.
Why This Matters Outside the Mouse House
RCC has become a poster child for both the promise and frustration of immunotherapy. The disease is immunogenic, yet response prediction remains messy, with PD-L1, gene-expression signatures, and imaging biomarkers all giving partial answers at best Rosellini et al., 2023; Posada Calderon et al., 2023. Researchers are now pushing toward more functional readouts, including granzyme B-based imaging in other cancers and newer urinary reporter systems that try to turn treatment response into something you can measure noninvasively Cheng et al., 2025.
So this paper fits a broader pattern: stop asking only "did the tumor change size?" and start asking "is the immune system actually hitting the target?" That is a much more satisfying question. It is also much more honest. Tumors are sneaky. Some shrink late. Some look stable while biology shifts underneath. Some throw enough confusion into the scan to make everyone in clinic stare at the image like it is a modern art exhibit.
The Catch, Because Biology Always Wants a Sequel
This is not ready to stroll into everyday oncology practice tomorrow. The imaging work is preclinical, and the patient urine set is small. We still need larger studies, cleaner comparisons with standard biomarkers, and proof that the signal really predicts outcomes across diverse patients and treatments.
Still, as puzzle pieces go, this one has sharp edges in a good way. It links immune cell function, kidney tumor biology, optical imaging, and urine testing into one framework. If that holds up, it could help doctors spot benefit earlier, spare some patients from ineffective treatment, and make immunotherapy monitoring feel a little less like reading tea leaves in a radiology suite.
References
-
Yang X, Liang B, Fu L, et al. Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma. Advanced Science. 2026:e24298. DOI: https://doi.org/10.1002/advs.202524298
-
Rosellini M, Marchetti A, Mollica V, et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology. 2023;20:133-157. DOI: https://doi.org/10.1038/s41585-022-00676-0
-
Posada Calderon L, Eismann L, Reese SW, Reznik E, Hakimi AA. Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature. Cancers (Basel). 2023;15(2):354. DOI: https://doi.org/10.3390/cancers15020354. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC9856305/
-
Scott JI, Mendive-Tapia L, Gordon D, et al. A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. Nature Communications. 2022;13:2366. DOI: https://doi.org/10.1038/s41467-022-29691-w
-
Cheng P, Zeng Z, Liu J, et al. Urinary bioorthogonal reporters for the monitoring of the efficacy of chemotherapy for lung cancer and of associated kidney injury. Nature Biomedical Engineering. 2025;9:686-699. DOI: https://doi.org/10.1038/s41551-024-01340-1
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.